Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076780 | 0.86 | MAOB (0.33) | MAOBTDP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14775559 | 0.83 | SMN1; SMN2 (0.34) | ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1096290 | 0.73 | CYP3A4 (0.35) | CYP3A4ABCG2MAOBALDH1A1HSD17B10 | |
| SCHEMBL3113441 | 0.73 | CYP3A4 (0.35) | CYP3A4ABCG2ALDH1A1HSD17B10TDP1 | |
| SCHEMBL789550 | 0.73 | CYP3A4 (0.35) | CYP3A4ABCG2ALDH1A1HSD17B10TDP1 | |
| SCHEMBL7047825 | 0.73 | CYP3A4 (0.35) | CYP3A4ABCG2ALDH1A1HSD17B10TDP1 | |
| SCHEMBL11789243 | 0.73 | MEN1 (0.37) | CYP3A4ABCG2ALDH1A1HSD17B10TDP1 | |
| SCHEMBL8472910 | 0.72 | ALDH1A1 (0.33) | CYP3A4ABCG2MAOBALDH1A1TAAR1 | |
| SCHEMBL5302174 | 0.69 | AHR (0.53) | CYP3A4ABCG2MAOBALDH1A1HSD17B10 | |
| SCHEMBL30787730 | 0.69 | AHR (0.53) | CYP3A4ABCG2MAOBALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100194-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-04-10 | — | — | US | claimed |
| EP-2029614-B1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | claimed |
| US-8338412-B2 | Inhibitors of P38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-25 | — | — | US | claimed |
| EP-1309560-B1 | Pyridine derivatives as inhibitors of p38 | VERTEX PHARMA (US) | 2012-10-03 | — | — | EP | claimed |
| US-8242275-B2 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-14 | — | — | US | claimed |
| US-8232391-B2 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-31 | — | — | US | claimed |
| US-20120053347-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-01 | — | — | US | claimed |
| US-20110281878-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | US | claimed |
| US-20110160163-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-30 | — | — | US | claimed |
| US-7951809-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | claimed |
| CN-1306512-A | Heterocyclic inhibitors of P38 | VERTEX PHARMA (US) | 2001-08-01 | — | — | CN | claimed |
| EP-1114039-A1 | INHIBITORS OF p38 | Vertex Pharmaceuticals Incorporated (US) | 2001-07-11 | — | — | EP | claimed |
| EP-1086085-A1 | INHIBITORS OF p38 | Vertex Pharmaceuticals Incorporated (US) | 2001-03-28 | — | — | EP | claimed |
| EP-1077943-A1 | HETEROCYCLIC INHIBITORS OF P38 | Vertex Pharmaceuticals Incorporated (US) | 2001-02-28 | — | — | EP | claimed |
| WO-2000017175-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-03-30 | — | — | WO | claimed |
| CN-1244867-A | Substituted nitrogen-containing heterocycles as P38 protein kinase inhibitors | VERTEX PHARMA (US) | 2000-02-16 | — | — | CN | claimed |
| WO-1999064400-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1999058502-A1 | HETEROCYCLIC INHIBITORS OF P38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-11-18 | — | — | WO | claimed |
| EP-0951467-A1 | SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE | Vertex Pharmaceuticals Incorporated (US) | 1999-10-27 | — | — | EP | claimed |
| WO-1998027098-A1 | SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160163-A1 | INHIBITORS OF p38 | ZAP70, MAPK1, MAP3K20 | CYP3A4 4862/4885ABCG2 4580/4885MAOB 3586/4885 |
| US-20110281878-A1 | INHIBITORS OF p38 | MAPK1, MAPK3, MAP3K1 | CYP3A4 4859/4885ABCG2 4092/4885MAOB 3756/4885 |
| US-20120053347-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | CYP3A4 1655/4885ABCG2 1715/4885MAOB 2313/4885 |
| US-20140100194-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | CYP3A4 1655/4885ABCG2 1715/4885MAOB 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.